# Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency

> **NCT02199496** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 5 (actual)

## Conditions studied

- Gastrointestinal Inflammation Associated With CVID
- CVID Enteropathy

## Interventions

- **BIOLOGICAL:** Stelara (ustekinumab)

## Key facts

- **NCT ID:** NCT02199496
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-19
- **Primary completion:** 2019-08-16
- **Final completion:** 2020-07-10
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2020-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02199496

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02199496, "Study of Safety, Tolerability, and Efficacy of Ustekinumab for Symptomatic Gastrointestinal Inflammation Associated With Common Variable Immunodeficiency". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02199496. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*